1 New onset COVID-19–related diabetes: an indicator of mortality

2 Jin-Kui Yang MD, PhD¹✉#, Jian-Min Jin MD, PhD^{2,3}✉#, Shi Liu, MD³✉, Peng Bai, MD^{2,3},
3 Wei He, MD^{4,3}, Fei Wu, MD³, Xiao-Fang Liu, MD, PhD², Zhong-Lin Chai, PhD⁶, De-Min Han
4 MD, PhD⁵

5 ¹Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing
6 100730, China. ✉Electronic address: jkyang@ccmu.edu.cn

7 ²Department of Respiratory and Critical Care Medicine, Beijing Tongren Hospital, Capital Medical
8 University, Beijing 100730, China.

9 ³Department of Internal Medicine, Union Hospital, Tongji Medical College, Huazhong University
10 of Science and Technology, Wuhan 430022, China.

11 ⁴Department of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University,
12 Beijing 100730, China.

13 ⁵Department of Otolaryngology and Head Surgery, Beijing Tongren Hospital, Capital Medical
14 University, Beijing 100730, China.

15 ⁶Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia

16

17 # These authors contributed equally to this paper.

18

19 ✉Address correspondence and reprint requests to

20 Professor Jin-Kui YANG, Department of Medicine, Beijing Tongren Hospital, Capital Medical
21 University, Beijing 100730, China

22 Tel: +86-10-58268445

23 Fax: +86-10-65288736

24 Cell: +86-13911167636

25 jkyang@ccmu.edu.cn

26 or

27 Dr. Jian-Min Jin, Department of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical
28 University, Beijing 100730, China.

29 Jian-Min Jin: jinjianmin1972@sina.com

30 or

31 Professor Shi Liu, Department of Internal Medicine, Union Hospital, Tongji Medical College,
32 Huazhong University of Science and Technology, Wuhan 430022, China.

33 E-mail: 1455019296@qq.com

34

Summary

Background Concomitance with diabetes is associated with high mortality in critical conditions. Patients with previous diabetes are more vulnerable to COVID-19. However, new-onset COVID-19–related diabetes (CRD) and its relevance have scarcely been reported. This study investigates new-onset CRD and its correlation with poor outcomes or death in patients with COVID-19.

Methods We performed a single center, retrospective case series study in 120 patients with laboratory confirmed COVID-19 at a university hospital. Fasting blood glucose (FBG) ≥ 7.0 mmol/L for two times during hospitalization and without a history of diabetes were defined as CRD. The *Critical* status was defined as admitted to intensive care unit (ICU) or death.

Results After excluding patients with a history of diabetes, chronic heart, kidney, and liver disease, 69 patients with COVID-19 were included in the final analysis. Of the 69 patients, 23 were *Moderate*, 20 were *Severe*, and 26 were *Critical* (including 16 deceased patients). The prevalence of CRD in *Critical* and *Moderate+Severe* patients was 53.85% and 13.95%, respectively. Kaplan-Meier survival analysis revealed a significantly higher mortality rate in patients with CRD ($P=0.0019$). Multivariable analysis indicated that CRD was an independent predictor for death (HR = 3.75, 95% CI 1.26-11.15). Cluster analysis suggested that indicators for multi-organ injury were interdependent, and more proximities of FBG with indicators for multi-organ injury was present.

Conclusion Our results suggest that new onset COVID-19–related diabetes is an indicator of multi-organ injury and predictor for poor outcomes and death in COVID-19 patients. As it is easy to perform for clinical practices and even self-monitoring, glucose testing will be much helpful for predicting poor outcomes to facilitate appropriate intensive care in patients with COVID-19.

Funding National Key Research and Development Program of China; The Beijing Science and Technology Project.

1 **Significance of this study**

2 **Evidence before this study**

3 Concomitance with diabetes is associated with high mortality in critical conditions.
4 Patients with previous diabetes are more vulnerable to COVID-19. However, new-onset
5 COVID-19–related diabetes (CRD) and its relevance have scarcely been reported.
6 Recently, an international group of leading diabetes researchers participating in the
7 CoviDIAB Project have established a global registry of patients with Covid-19–related
8 diabetes (covidiab.e-dendrite.com).

9 **Added value of this study?**

10 New-onset diabetes in COVID-19 defined as CRD was investigated. Correlation
11 between CRD and poor outcomes or death in patients with COVID-19 was found.
12 About half of the *Critical* patients have new onset CRD. CRD is the representative of
13 the clustered indicators of multi-organ injury and is the predictor for poor outcomes and
14 death.

15 **How might these results change the focus of research or clinical practice?**

16 Our results suggest that new onset diabetes is an indicator of multi-organ injury and
17 predictor for poor outcomes and death in COVID-19 patients. The study of CRD may
18 also uncover novel mechanisms of disease.

19

1 Introduction

2 In early December 2019, an outbreak of a novel coronavirus (SARS-CoV-2) pneumonia
3 disease (COVID-19) occurred in Wuhan, China.[1] Most patients with COVID-19 were
4 *Mild. Moderate* patients often experienced dyspnea after one week. Some *Severe*
5 patients progressed rapidly to *Critical* condition including multi-organ failure and even
6 death.[2-5]

7 Recently, new-onset diabetes in COVID-19 is noticed. An international group of
8 leading diabetes researchers participating in the CoviDIAB Project have established a
9 global registry of patients with Covid-19–related diabetes (covidiab.e-dendrite.com).
10 [6] COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-
11 CoV-2) infection. It is reminiscent of the SARS-CoV outbreak in early 2003, because
12 both coronavirus attack cells via the same receptor, angiotensin-converting enzyme 2
13 (ACE2). [1]

14 We have previously reported that acute diabetes was commonly present in SARS
15 patients without prior history of diabetes and without using glucocorticoids, and was an
16 independent predictor for mortality in SARS patients.[7] Binding of SARS coronavirus
17 to the angiotensin-converting enzyme 2 (ACE2) receptor may damage islets and causes
18 acute diabetes.[8] *ACE2* gene knockout leads to diabetes in mice.[9]

19 ACE2 are expressed in key metabolic organs and tissues, including pancreatic islet
20 cells,[10] the small intestine, adipose tissue, and the kidneys.[11] Thus, it is plausible
21 that COVID-19 may have pleiotropic alterations of glucose metabolism or new type of
22 disease.[6] In this observational cohort study, we aim to explore the correlation between
23 COVID-19–related diabetes (CRD) and poor outcomes or death in patients with
24 COVID-19.

25

1 **Methods**

2 **Participants**

3 This retrospective cohort study included consecutive COVID-19 adult inpatients (≥ 18
4 years old) admitted to Wuhan Union Hospital (Wuhan, China) and treated by the
5 supportive medical team of Beijing Tongren Hospital (Beijing, China) from January 29,
6 2020, to March 20, 2020. A uniformed protocol of clinical practices was used in this
7 cohort.

8 Respiratory specimens were collected by the local center for disease control and
9 prevention (CDC) and then shipped to designated authoritative laboratories to detect
10 SARS-CoV-2. The presence of SARS-CoV-2 in respiratory specimens was detected by
11 real-time RT-PCR methods. The RT-PCR assay was conducted as per the protocol
12 established by the World Health Organization (WHO).

13 The clinical outcomes including admitted to intensive care unit (ICU) or in-hospital
14 death were monitored up to March 24, 2020, the final date of follow-up.

15 **Exclusion criteria:** (1) Patients with a history of diabetes were excluded. (2) To avoid
16 glucocorticoid-induced diabetes, patients who received glucocorticoid treatment were
17 also excluded. (3) For the identification of indicators of early multi-organ injury for
18 predicting poor outcomes, patients with chronic organ damage, including heart disease
19 (myocardial infarction and heart failure), kidney disease (maintenance dialysis or renal
20 transplantation), or liver disease (liver cirrhosis) were excluded.

21 **COVID-19-related diabetes:** FBG ≥ 7.0 mmol/L for two times during hospitalization
22 and without a history of diabetes in COVID-19 patients were defined as CRD.

23 **Clinical classification of COVID-19:** Diagnosis and clinical classification criteria and
24 treatment plan (version 6.0) of COVID-19 was launched by the National Health
25 Committee of China (<http://www.nhc.gov.cn/>). The clinical classification of severity is

as follows: (1) *Mild*, having only mild symptoms, imaging shows no pneumonia. (2) *Moderate*, with fever, respiratory tract symptoms, and imaging shows pneumonia. (3) *Severe*, meet any of the following signs: a) respiratory distress, respiratory rate ≥ 30 beats / min; b) in the resting state, finger oxygen saturation $\leq 93\%$ arterial blood oxygen partial pressure (PaO_2 /oxygen concentration (FiO_2) $\leq 300\text{mmHg}$ ($1\text{mmHg} = 0.133\text{kPa}$). (4) *Critical*, one of the following conditions: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.

The Research Ethics Commission of Beijing Tongren Hospital, Capital Medical University (TRECKY2020-013) approved the study and the Ethics Commission waived the requirement for informed consent.

Data collection

Demographic, clinical, laboratory and outcome data were extracted from the electronic hospital information system using a standardized form. All medical data were checked by two medical doctors (JMJ and PB) and the leader author (JKY) adjudicated any different interpretation between the two medical doctors.

Statistical analysis

Data were expressed as median (interquartile range (IQR)) or percentage, as appropriate. Comparison of continuous data among different severity groups were determined using a Kruskal-Wallis test. Chi-square tests were used for categorical variables. Proximity Matrix of six measures as different organ damage indicators were calculated by Hierarchical cluster analysis. To find the risk factors predicting in-hospital death, univariate and multivariate Cox proportional hazard model were used to calculated hazard ratio (HR). Kaplan–Meier survival curves and the log-rank test were used for testing the survival between normal and abnormal indicators. SPSS for Windows 17.0

1 and Graphpad prism 7.0 software were used for statistical analysis, with statistical
2 significance set at 2-sided $P < 0.05$.

3 **Results**

4 ***Demographic and clinical characteristics***

5 A total of 120 consecutive COVID-19 adult inpatients (≥ 18 years old) were admitted to
6 Wuhan Union Hospital (Wuhan, China) and treated by the supportive medical team of
7 Beijing Tongren Hospital (Beijing, China) from January 29, 2020 to March 20, 2020.
8 Because Wuhan Union Hospital was assigned responsibility for the treatments of severe
9 COVID-19 patients by the Wuhan government, most patients were *Severe* or *Critical*,
10 some were *Moderate*, but none were *Mild*.

11 After excluding patients received glucocorticoid treatment or with a history of
12 diabetes, myocardial infarction, heart failure, dialysis, renal transplant, cirrhosis, and
13 patients missing basic medical information, 69 patients were included in the final
14 analysis. Of the 69 patients, 23 were *Moderate*, 20 were *Severe*, and 26 were *Critical*
15 (including 16 deceased patients). The median age of the 69 patients was 61 years (IQR,
16 52 to 67). Older patients tend to be more serious ($p = 0.024$). The ratio of male to female
17 patients were relatively similar, with 49.3% males. However, the proportion of males
18 in deceased patients were 81.2%, suggestive that males may have higher mortality from
19 COVID-19 ($P = 0.003$). Fever (89.9%), cough (65.2%) and dyspnea (43.5%) were the most
20 common symptoms, while sputum (17.4%) and diarrhea (17.4%) were less common.

21 An increase in white blood cells and neutrophils, and decrease in lymphocytes and
22 platelets occurred in *Critical* patients at the time of admission. A decrease of albumin,
23 an increase of globulin, and an increase of C-reactive protein was also present in
24 *Critical* patients (Table 1).

25 ***COVID-19-related diabetes and mortality***

1 The prevalence of CRD in *Critical* and *Moderate+Severe* patients was 53.85% and
2 13.95%, respectively (Figure 1 A and B). Kaplan-Meier survival analysis revealed a
3 significantly higher mortality rate in patients with CRD ($P=0.0019$) (Figure 1C).

4 ***Longitudinal changes of FBG and mortality***

5 FBG level was much higher above the criteria of diagnosis of diabetes in *Critical* group,
6 while it did not increase remarkably in *Moderate+Severe* group (Figure 1B).
7 Considering that the deaths happened only in *Critical* patients in this cohort, a
8 longitudinal case-control investigation was conducted in *Critical* patients. In 26
9 *Critical* patients who were measured once every three days and at least three times were
10 analyzed, while those who did not have >3 measurements were not included for analysis.
11 Although FBG levels were much higher above the upper limit of normal value at the
12 time of admission, they dramatically decreased to the normal range during subsequent
13 treatment in survivors. However, of the patients who died, increases of FBG levels
14 continued (Figure 1D-E).

15 ***FBG as a predictor for multi-organ injury and mortality***

16 Lactate dehydrogenase (LDH)/hydroxybutyrate dehydrogenase (HBDH), creatinine
17 (Cr), and alanine aminotransferase (ALT) were used as the relative function of multiple
18 organs (i.e., the heart, kidney, and liver function, respectively). Cluster analysis
19 suggested that some definite indicators for multi-organ injury were independent and
20 that multi-organ injury caused by the virus infection might present. Most interestingly,
21 significant proximities or interdependent of FBG with other Variables including LDH
22 ($r=0.433$, $P<0.01$), HDDH ($r=0.43$, $P<0.01$), and Cr ($r=0.498$, $P<0.01$) were present.
23 (Table 2).

24 Using the univariable Cox proportional hazards model, male sex (HR = 5.02, 95%
25 CI 1.43-17.62), elevated FBG (HR = 5.09, 95% CI 1.76-14.70), LDH (HR = 9.73, 95%

1 CI 1.28-73.7) and HBDH (HR = 3.81, 95% CI 1.23-11.85) were predictors for death
2 (Figure 2A). In the multivariable model, elevated FBG remained the independent
3 predictor for death (HR = 3.75, 95% CI 1.26-11.15) (Figure 2B).

4 Discussion

5 This study has shown that new-onset diabetes is very common in COVID-19. The
6 prevalence of CRD in *Critical* and *Moderate+Severe* patients was 53.85% and 13.95%,
7 respectively. The results also suggest that CRD is an indicator of multi-organ injury and
8 predictor for poor outcomes and death in COVID-19 patients.

9 Except pneumonia, the multi-organ nature of COVID-19 or SARS-CoV-2 infection
10 has been demonstrated in a latest autopsy studies.[12] Moreover, an autopsy study on 3
11 cases of SARS indicate that some lesions observed in heart, kidney, pancreas may have
12 existed before the hospitalization.[13] We found that ACE2, the SARS-CoV-2 receptor,
13 is highly expressed in the pancreatic islet.[10]

14 Subacute islet injury caused by virus infection has been widely reported in type 1
15 diabetes, which is an autoimmune disease characterized by a long-term loss of
16 pancreatic islet β -cells. Acute pancreatic islet injury induced diabetes caused by virus
17 infection has scarcely been reported. However, serological evidence of infection and
18 isolation of viruses including Coxsackie B and Mumps from the pancreas have been
19 reported in a few cases of acute diabetes.[14] A case-control study indicated that high
20 FBG is an independent predictor for severity of H1N1 pneumonia. In the study, FBG
21 was remarkably increased in patients with H1N1 pneumonia than in patients with non-
22 H1N1 pneumonia (8.3 vs. 6.2 mmol/L). Moreover, compensative rise in insulin, in
23 corresponding with high FBG was not found; instead, islet β -cells function indicated
24 by HOMA- β index is lower (103 vs. 134).[15] We have previously reported that
25 hyperglycemia is an independent predictor for death in SARS patients.[7] Binding of

1 SARS coronavirus to the ACE2 receptor may lead to impairment of the function of
2 ACE2 and the functional loss of ACE2, as observed in the ACE2 KO mice, is known
3 to cause diabetes.[9] Furthermore, coronavirus can use the ACE2 on the islet cells as
4 its receptor to enter and replicate within the islet cells, leading to damage of islet cells,
5 such as insulin producing β cells, ultimately leading to insulin deficiency, a direct cause
6 of acute diabetes, as observed in SARS patients.[8]

7 It is appreciated that FBG elevation can be a result of “Stress hyperglycemia” during
8 acute illness in patients with COVID-19. However, severe hyperglycemia can also be
9 caused by either insulin deficiency or insulin resistance. Insulin resistance caused by
10 metabolic, hormonal, and cytokine changes as a result of illness is usually associated
11 with a corresponding rise in insulin output, which is a compensation mechanism to
12 maintain normal glycemia. Only when the insulin resistance was too severe and the
13 compensation failed, the level of blood glucose would increase significantly [16, 17].
14 Therefore, relative dysfunction of pancreatic islet insulin secretion caused by the virus
15 infection could be a main reason for the severe hyperglycemia observed in patients with
16 COVID-19.

17 Our results suggest that increased level of blood glucose is a representative of the
18 clustered multi-organ injury indicators and an earlier predictor for poor outcomes,
19 including death in these patients. Acute heart injury such as acute myocarditis is
20 common in patients with infection of various viruses, such as adenovirus, herpesvirus
21 and enterovirus [18]. Since myocarditis associated with coronavirus infection was
22 firstly reported in 1980 [19], a growing body of evidence shows that coronavirus is also
23 a pathogen for heart injury that should not be ignored. [8, 20] The latest case report has
24 described cardiac injury in a patient with COVID-19.[21] Two myocardial enzymes,
25 LDH and HBDH are known to be released into the circulation as a result of the

1 myocardial injury. In this study, we found that high levels of both LDH and HBDH in
2 patients on admission were predictor for severity and in-hospital death. Acute kidney
3 injury is also common in patients with virus infection, such as Parvovirus B19, Hanta,
4 Ebola, and Dengue virus infection.[22] Coronavirus associated kidney injury was
5 reported in patients with MDRS.[23] In the previous report, we found that SARS-CoV
6 may cause kidney injury and elevated Cr is an independent predictor for in-hospital
7 death in SARS patients.[8] In this study, we found high Cr were predictor for in-hospital
8 death in COVID-19 patients.

9 There are several limitations in our study. First, we only assessed FBG and some
10 most accessible biochemical parameters. It would have produced better results if some
11 more specific indicators such as serum insulin levels, echocardiography, glomerular
12 filtration rate were measured in this study. Second, interpretation might be limited by
13 the sample size of the study. Last but not least, missing of HbA1c level is a limitation.
14 Because, low HbA1c would indicate no history of recent diabetes and support the
15 confirmation of new onset of diabetes.

16 In summary, except pneumonia, multi-organ injury including the heart, kidney, and
17 possibly pancreatic islet injuries can cause CRD at an early stage and thereby increase
18 the risk of mortality in patients with COVID-19, if hyperglycemia cannot be improved
19 as shown in Fig 1. These multi-organ injury indicators were associated with higher odds
20 of death and were interdependent, indicating that the multi-organ damage happened at
21 the same time. Among them, COVID-19-related diabetes is a representative of the
22 clustered multi-organ injury for predicting mortality of COVID-19. As it is easy to
23 perform for clinical practices and self-monitoring, blood glucose testing will be much
24 helpful for predicting critical condition to facilitate appropriate intensive care.

25

1 **Contributions.** MJM, PB, FG, WH, SL, FW, DMH SL and JKY collected the
2 epidemiological and clinical data and processed statistical data. JKY drafted the
3 manuscript. JKY, MJM, SL and CZL revised the final manuscript. JKY is responsible for
4 summarizing all epidemiological and clinical data.

5 **Declaration of interests.** We declare no competing interests.

6 **Acknowledgments.** This study was funded by the National Key R&D Program of
7 China (2017YFC0909600). The funder has no role in study design, data collection, data
8 analysis, manuscript preparation and/or publication decisions. We thank all patients
9 involved in the study.

10 **References**

- 11 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, *et al.* A Novel Coronavirus from Patients with
12 Pneumonia in China, 2019. *N Engl J Med* 2020.
- 13 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al.* Clinical features of patients infected with 2019
14 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**:497-506.
- 15 3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, *et al.* Epidemiological and clinical characteristics
16 of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;
17 **395**:507-513.
- 18 4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, *et al.* Clinical Characteristics of 138 Hospitalized
19 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.
- 20 5. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, *et al.* Clinical findings in a group of patients
21 infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case
22 series. *BMJ* 2020; **368**:m606.
- 23 6. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, *et al.* New-Onset Diabetes in
24 Covid-19. *N Engl J Med* 2020.
- 25 7. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, *et al.* Plasma glucose levels and diabetes are
26 independent predictors for mortality and morbidity in patients with SARS. *Diabet Med* 2006; **23**:623-
27 628.
- 28 8. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and
29 causes acute diabetes. *Acta Diabetol* 2010; **47**:193-199.
- 30 9. Niu MJ, Yang JK, Lin SS, Ji XJ, Guo LM. Loss of angiotensin-converting enzyme 2 leads to
31 impaired glucose homeostasis in mice. *Endocrine* 2008; **34**:56-61.
- 32 10. Fang HJ, Yang JK. Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat
33 pancreas. *J Int Med Res* 2010; **38**:558-569.
- 34 11. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2
35 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.
36 *J Pathol* 2004; **203**:631-637.

12. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, *et al.* [A pathological report of three COVID-19 cases by minimally invasive autopsies]. *Zhonghua Bing Li Xue Za Zhi* 2020; **49**:E009.
13. Lang Z, Zhang L, Zhang S, Meng X, Li J, Song C, *et al.* Pathological study on severe acute respiratory syndrome. *Chin Med J (Engl)* 2003; **116**:976-980.
14. Jaeckel E, Manns M, Von Herrath M. Viruses and diabetes. *Ann N Y Acad Sci* 2002; **958**:7-25.
15. Wang W, Chen H, Li Q, Qiu B, Wang J, Sun X, *et al.* Fasting plasma glucose is an independent predictor for severity of H1N1 pneumonia. *BMC Infect Dis* 2011; **11**:104.
16. Gupta D, Krueger CB, Lastra G. Over-nutrition, obesity and insulin resistance in the development of beta-cell dysfunction. *Curr Diabetes Rev* 2012; **8**:76-83.
17. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. *Lancet* 2009; **373**:1798-1807.
18. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis--diagnosis, treatment options, and current controversies. *Nat Rev Cardiol* 2015; **12**:670-680.
19. Riski H, Hovi T, Frick MH. Carditis associated with coronavirus infection. *Lancet* 1980; **2**:100-101.
20. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. *Ann Saudi Med* 2016; **36**:78-80.
21. Inciardi RM, Lupi L, Zacccone G, Italia L, Raffo M, Tomasoni D, *et al.* Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020.
22. Prasad N, Novak JE, Patel MR. Kidney Diseases Associated With Parvovirus B19, Hanta, Ebola, and Dengue Virus Infection: A Brief Review. *Adv Chronic Kidney Dis* 2019; **26**:207-219.
23. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. *Virol J* 2015; **12**:222.

Figure 1. COVID-19-related diabetes and mortality

- (A) Prevalence of COVID-19-related diabetes in *Critical* and *Moderate+Severe* groups.
- (B) Fasting blood glucose levels in *Critical* and *Moderate+Severe* groups.
- (C) Kaplan-Meier survival curves for in-hospital death rate of patients with COVID-19.
- (D-E) Longitudinal observation of Fasting blood glucose during admission and subsequent treatment.

Figure 2. Effects of multi-organ injury indicators on the risk of in-hospital death in patients with COVID-19.

(A) Univariable Cox regression indicated effects of multi-organ injury indicators on predicting in-hospital death.

(B) Multivariable Cox regression indicated effects of independent multi-organ injury indicators on predicting in-hospital death.

Table 1: Demography, clinical and laboratory parameters of patients with COVID-19

	All patients (n=69)	Severity			P value
		Moderate (n=23)	Severe (n=20)	Critical (n=26)	
Age—yrs	61 (52-67)	56 (47-64)	62 (55-67)	65 (57-71)	0.024 ‡
Male sex—n (%)	34 (49.3)	9 (39.1)	8 (40.0)	16 (61.5)	0.111#
Symptoms					
Fever—n (%)	62 (89.9)	18 (78.3)	19 (95.0)	25 (96.2)	0.041 #
Cough—n (%)	45 (65.2)	13 (56.5)	13 (65.0)	19 (73.1)	0.225#
Sputum—n (%)	12 (17.4)	5 (21.7)	4 (20.0)	3 (11.5)	0.341#
Dyspnea—n (%)	30 (43.5)	7 (30.4)	7 (35.0)	16 (61.5)	0.026 #
Fatigue—n (%)	26 (37.7)	8 (34.8)	6 (30.0)	12 (46.2)	0.397#
Diarrhea—n (%)	12 (17.4)	2 (8.7)	5 (25.0)	5 (19.2)	0.350#
From onset to hospitalization—days	12.0 (9.0-14.0)	13.0 (10.0,15.0)	11.5 (7.8,14.0)	12.0 (7.0,14.0)	0.273‡
Haemoglobin—g/L	127 (116-139)	124 (117-137)	119 (110-143)	130 (121-147)	.477‡
Platelet count— $\times 10^9/L$	211(183-282)	215 (192-286)	215 (196-293)	205 (159-263)	.515‡
White blood cell count— $\times 10^9/L$	6.2 (4.7-8.2)	5.7 (4.3-7.4)	5.9 (4.8-8.1)	7.7 (5.9-9.7)	.009 ‡
Neutrophil count— $\times 10^9/L$	4.5 (3.1-6.7)	3.3 (2.7-4.9)	4.2 (3.7-5.9)	6.7 (5.4-8.8)	.000 ‡
Lymphocyte count— $\times 10^9/L$	1.0 (0.7-1.4)	1.3 (0.9-1.7)	0.9 (0.7-1.4)	0.7 (0.4-1.1)	.000 ‡
Potassium—mmol/L	3.9 (3.5-4.3)	4.1 (3.9-4.4)	3.8 (3.5-4.5)	3.7 (3.2-4.0)	.025 ‡
Sodium—mmol/L	139 (137-142)	140 (138-142)	141 (138-143)	138 (135-141)	.078‡
Chloride—mmol/L	104 (99-106)	105 (102-106)	104 (100-108)	103 (98-105)	.109‡
Albumin—g/L	29 (27-34)	34 (30-39)	28 (26-31)	28 (25-30)	.001 ‡
Globulin—g/L	32 (29-36)	30 (26-34)	32 (30-38)	34 (30-39)	.027 ‡
C-reactive protein—mg/L	36 (5-77)	4 (1-36)	23 (7-65)	60 (47-100)	.000 ‡
Alanine aminotransferase—U/L	38 (24-52)	39 (21-49)	37 (24-55)	36 (27-52)	.641‡
Aspartate aminotransferase—U/L	33 (23-47)	23 (17-34)	35 (28-50)	35 (29-56)	.007 ‡
Alkaline phosphatase—U/L	57 (48-67)	55 (46-70)	55 (41-62)	61 (53-79)	.067‡
Lactate dehydrogenase—U/L	312 (204-483)	196 (137-251)	294 (242-384)	499 (354-587)	.000 ‡
Hydroxybutyrate dehydrogenase—U/L	253 (190-368)	161 (118-218)	252 (192-329)	387 (313-478)	.000 ‡
Creatine kinase—U/L	61 (47-143)	48 (36-66)	65 (41-122)	107 (54-275)	.007 ‡
Creatine kinase—MB—U/L	12 (9-19)	9 (7-12)	13 (9-21)	14 (10-23)	.006 ‡
Blood urea nitrogen—mmol/L	5.0 (3.4-6.7)	4.2 (3.3-5.5)	4.5 (2.9-6.9)	5.4 (4.0-7.7)	.158‡
Creatinine— $\mu\text{mol/L}$	66 (53-84)	64 (52-70)	61 (51-92)	70 (58-93)	.121‡
Fasting Blood Glucose—mmol/L	6.5 (5.7-7.6)	5.7 (5.3-6.5)	6.3 (5.6-6.8)	7.5 (6.4-8.7)	.000 ‡

Data are median (IQR) or n (%). P values were calculated by Kruskal-Wallis Test (‡) or χ^2 test (#), as appropriate for group comparison analyses.

Table 2: Proximity matrix of six multi-organ injury indicators by Hierarchical cluster analysis

	FBG	LDH	Cr	CK	HDDH	ALT
FBG	1					
LDH	**0.433	1				
Cr	**0.498	0.265	1			
CK	0.025	*0.328	0.113	1		
HDDH	**0.428	**0.881	0.128	**0.385	1	
ALT	0.099	**0.441	0.258	0.017	0.246	1

FBG: Fasting Blood Glucose; LDH: Lactate dehydrogenase; Cr: Creatinine; CK: Creatine kinase; HDDH: Hydroxybutyrate dehydrogenase; ALT: Alanine aminotransferase.

** p<0.01; * P<0.05. Hierarchical cluster analysis, Pearson correlation test (2-tailed).